Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line

Stéphanie Dulucq (1, 2) , Gabriel Etienne (2, 3) , Stéphane Morisset (4) , Emilie Klein , Claudine Chollet (5) , Fanny Robbesyn (5) , Béatrice Turcq (2) , Isabelle Tigaud (6) , Sandrine Hayette (7) , Franck Nicolini (8) , François-Xavier Mahon (3, 2)

1 Laboratory of Hematology, Bordeaux University Hospital, Avenue de Magellan, 33604, Pessac
2 Laboratory of Mammary and Leukaemic Oncogenesis, INSERM U1218, Université de Bordeaux
3 Institut Bergonié [Bordeaux]
4 Hôpital Edouard Herriot [CHU - HCL]
5 Laboratory of Hematology, Bordeaux University Hospital, Avenue de Magellan, 33604, Pessac
6 Laboratory of Hematology, Centre Hospitalier Lyon Sud
7 Service d'hématologie [Hôpital Edouard Herriot - HCL]
8 Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL]

Domaines: Sciences du Vivant [q-bio]; Biologie moléculaire; Cancer; Hématologie

Stéphanie Dulucq, Gabriel Etienne, Stéphane Morisset, Emilie Klein, Claudine Chollet, et al.. Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line. Annals of Hematology, 2019, 98 (5), pp.1159-1168. ⟨10.1007/s00277-019-03633-x⟩. ⟨hal-02396000⟩